The future of predictive biosimulation in drug discovery

Biosimulation and mathematical modeling are powerful approaches for characterizing complex biological systems and their dynamic evolution. The modeling process enables research scientists to systematically identify critical gaps in their knowledge and explicitly formulate candidate hypotheses to span them. Biosimulations are being used to explore “what if” scenarios that can lead to recommendations for designing the best, most informative ‘next experiment.’ This targeted approach to assay development, data interpretation and decision making promises to dramatically narrow the ‘predictability gap’ between drug discovery and clinical development.

[1]  Vikram Sinha,et al.  Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation , 2005, The AAPS Journal.

[2]  Seth Michelson,et al.  The impact of systems biology and biosimulation on drug discovery and development. , 2006, Molecular bioSystems.

[3]  A. Kansal,et al.  Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design. , 2005, Systems biology.

[4]  K. O. Elliston,et al.  Inferring Gene Regulatory Networks from Raw Data: A Molecular Epistemics Approach , 2004, Pacific Symposium on Biocomputing.

[5]  Christina M. Friedrich,et al.  In silico predictions of target clinical efficacy , 2004 .

[6]  C J Musante,et al.  Small- and large-scale biosimulation applied to drug discovery and development. , 2002, Drug discovery today.

[7]  James L. Gilbert,et al.  Rebuilding Big Pharma ’ s Business Model , 2022 .

[8]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[9]  L. Greller,et al.  The dynamics of molecular networks: applications to therapeutic discovery. , 2001, Drug discovery today.

[10]  Z. Agur,et al.  Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids. , 2005, European journal of cancer.

[11]  Z. Agur,et al.  The growth law of primary breast cancer as inferred from mammography screening trials data. , 1998, British Journal of Cancer.

[12]  Richard Li-Xiang Ho,et al.  Biosystems modelling for in silico target validation: challenges to implementation , 2000 .

[13]  Noble,et al.  Biological simulations in drug discovery. , 1999, Drug discovery today.

[14]  D. Noble.  Modeling the Heart--from Genes to Cells to the Whole Organ , 2002, Science.

[15]  Christopher H. Bryant,et al.  Functional genomic hypothesis generation and experimentation by a robot scientist , 2004, Nature.

[16]  Z. Agur,et al.  A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth , 2004, Angiogenesis.

[17]  S. Holgate,et al.  The Roles of Cells and Mediators in a Computer Model of Chronic Asthma , 2001, International Archives of Allergy and Immunology.

[18]  Arup K Chakraborty,et al.  In silico models for cellular and molecular immunology: successes, promises and challenges , 2003, Nature Immunology.

[19]  Assessing the impact of biosimulation on target selection and validation , 2003 .

[20]  Seth Michelson,et al.  In silico prediction of clinical efficacy. , 2006, Current opinion in biotechnology.

[21]  Seth Michelson,et al.  Chapter 27. Biosimulation: Dynamic modeling of biological systems , 2002 .